Literature DB >> 30002211

Azathioprine-induced pancytopenia with normal TPMT activity presenting with HSV oral ulcers.

Caroline H Jensen1, John Tiu2, Jillian S Catalanotti2.   

Abstract

A 65-year-old man with treatment-resistant psoriatic arthritis, hypertension, dyslipidaemia and benign prostatic hyperplasia (BPH) presented with herpes simplex virus (HSV) oral ulcers and a recent 15 lb weight loss due to reduced consumption. Five weeks previously, his methotrexate was tapered and he had begun taking azathioprine. The patient's thiopurine S-methyltransferase (TPMT) activity level was normal prior to starting azathioprine. He was found to have pancytopenia with normal folate levels and azathioprine was discontinued. His pancytopenia worsened, with a nadir 8 days after stopping azathioprine, before returning to normal levels. His oral ulcers improved and he was able to tolerate solid food. This case illustrates that decreased TPMT activity is not the only risk factor for pancytopenia as an adverse reaction to azathioprine. Furthermore, HSV stomatitis may be the presenting symptom of pancytopenia. The timeline of improvement in cell counts illustrated in this patient has implications for the management of suspected azathioprine-induced pancytopenia. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  contraindications and precautions; haematology (drugs and medicines); malignant disease and immunosuppression; safety; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2018        PMID: 30002211      PMCID: PMC6047726          DOI: 10.1136/bcr-2018-225209

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  [Azathioprine-associated severe myelosuppression: indication of routine determination of thiopurine S-methyltransferase variant?].

Authors:  S Ngo; G Sauvetre; O Vittecoq; H Lévesque; I Marie
Journal:  Rev Med Interne       Date:  2010-10-20       Impact factor: 0.728

3.  Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase.

Authors:  M Konstantopoulou; A Belgi; K D Griffiths; J R C Seale; A W Macfarlane
Journal:  BMJ       Date:  2005-02-12

4.  Immunosuppressive therapy: guidelines for drug dosage. Depression of bone marrow granulocyte reserves in systemic lupus erythematosus.

Authors:  H E Paulus; R Okun; J J Calabro
Journal:  Arthritis Rheum       Date:  1972 Jan-Feb

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 6.  The differential diagnosis and bone marrow evaluation of new-onset pancytopenia.

Authors:  Elizabeth P Weinzierl; Daniel A Arber
Journal:  Am J Clin Pathol       Date:  2013-01       Impact factor: 2.493

7.  Pancytopenia in systemic lupus erythematosus related to azathioprine.

Authors:  J C Nossent; A J Swaak
Journal:  J Intern Med       Date:  1990-01       Impact factor: 8.989

Review 8.  Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.

Authors:  G P R Clunie; L Lennard
Journal:  Rheumatology (Oxford)       Date:  2003-10-17       Impact factor: 7.580

9.  Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.

Authors:  L Lennard; J A Van Loon; J S Lilleyman; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

10.  Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism.

Authors:  U Boonsrirat; S Angsuthum; S Vannaprasaht; J Kongpunvijit; N Hirankarn; W Tassaneeyakul; Y Avihingsanon
Journal:  Lupus       Date:  2008-02       Impact factor: 2.911

View more
  1 in total

1.  A Case of Pancytopenia with Many Possible Causes: How Do You Tell Which is the Right One?

Authors:  Priscila Diaz; Mariana Abreu Vieira; António Carneiro; Natália Fernandes
Journal:  Eur J Case Rep Intern Med       Date:  2019-01-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.